ValuEngine upgraded shares of Heron Therapeutics (NASDAQ:HRTX) from a sell rating to a hold rating in a research report released on Sunday, December 31st.
Several other brokerages have also recently issued reports on HRTX. Cantor Fitzgerald restated a buy rating on shares of Heron Therapeutics in a research note on Monday, September 25th. Mizuho started coverage on Heron Therapeutics in a report on Tuesday, September 26th. They set a buy rating and a $28.00 price target on the stock. Northland Securities started coverage on Heron Therapeutics in a research report on Wednesday, September 27th. They issued an outperform rating and a $40.00 price target for the company. Noble Financial reiterated a buy rating and issued a $24.00 price target on shares of Heron Therapeutics in a research report on Friday, October 6th. Finally, Oppenheimer started coverage on Heron Therapeutics in a research report on Monday, October 30th. They issued a buy rating and a $27.00 price target for the company. Three investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Heron Therapeutics currently has a consensus rating of Buy and a consensus target price of $28.82.
Shares of Heron Therapeutics (HRTX) traded up $1.55 on Friday, reaching $20.35. 1,656,600 shares of the company’s stock traded hands, compared to its average volume of 1,034,243. The firm has a market cap of $1,120.00, a PE ratio of -5.37 and a beta of 2.12. Heron Therapeutics has a 12 month low of $12.21 and a 12 month high of $20.55. The company has a quick ratio of 2.02, a current ratio of 2.12 and a debt-to-equity ratio of 0.62.
Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.10. The firm had revenue of $8.57 million during the quarter, compared to the consensus estimate of $8.12 million. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. sell-side analysts anticipate that Heron Therapeutics will post -3.39 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Janus Henderson Group PLC purchased a new stake in shares of Heron Therapeutics during the 2nd quarter worth about $78,134,000. Virtu KCG Holdings LLC raised its stake in shares of Heron Therapeutics by 62.5% in the 2nd quarter. Virtu KCG Holdings LLC now owns 25,053 shares of the biotechnology company’s stock valued at $347,000 after acquiring an additional 9,637 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Heron Therapeutics by 7.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 204,857 shares of the biotechnology company’s stock valued at $2,837,000 after acquiring an additional 14,086 shares in the last quarter. C WorldWide Group Holding A S bought a new position in shares of Heron Therapeutics in the 3rd quarter valued at approximately $1,615,000. Finally, Alyeska Investment Group L.P. raised its stake in shares of Heron Therapeutics by 9.5% in the 3rd quarter. Alyeska Investment Group L.P. now owns 754,657 shares of the biotechnology company’s stock valued at $12,188,000 after acquiring an additional 65,260 shares in the last quarter. Hedge funds and other institutional investors own 98.78% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Heron Therapeutics (HRTX) Upgraded at ValuEngine” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/11/heron-therapeutics-hrtx-lifted-to-hold-at-valuengine.html.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.